Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Free Report) has earned an average rating of “Moderate Buy” from the five research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month […]
Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Free Report) have earned a consensus rating of “Moderate Buy” from the five ratings firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year […]
Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month target […]
Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Free Report) have been given an average recommendation of “Moderate Buy” by the five analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average […]
Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Free Report) passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $1.22 and traded as low as $1.11. Seres Therapeutics shares last traded at $1.14, with a volume of 3,498,757 shares. Analyst Ratings Changes Separately, StockNews.com initiated […]